EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, TaiwanJ Pharmaceuticals Co's Enterprise Value is NT$505.23 Mil.
TaiwanJ Pharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-24.46 Mil. Therefore, TaiwanJ Pharmaceuticals Co's EV-to-FCF for today is -20.66.
The historical rank and industry rank for TaiwanJ Pharmaceuticals Co's EV-to-FCF or its related term are showing as below:
ROCO:6549'
s EV-to-FCF Range Over the Past 10 Years
Min: -468.46 Med: -73.44 Max: 64.54
Current: -20.66
During the past 13 years, the highest EV-to-FCF of TaiwanJ Pharmaceuticals Co was 64.54. The lowest was -468.46. And the median was -73.44.
ROCO:6549's EV-to-FCF is ranked worse than 100% of 331
companies
in the Biotechnology industry
Industry Median: 16.48
vs ROCO:6549: -20.66
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TaiwanJ Pharmaceuticals Co (ROCO:6549) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TaiwanJ Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
TaiwanJ Pharmaceuticals Co's share price for today is NT$7.13.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TaiwanJ Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.300.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
TaiwanJ Pharmaceuticals Co EV-to-FCF Related Terms
TaiwanJ Pharmaceuticals Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6549 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, TaiwanJ Pharmaceuticals Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiwanJ Pharmaceuticals Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiwanJ Pharmaceuticals Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where TaiwanJ Pharmaceuticals Co's EV-to-FCF falls into.
TaiwanJ Pharmaceuticals Co's current Enterprise Value is NT$505.23 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TaiwanJ Pharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-24.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiwanJ Pharmaceuticals Co (ROCO:6549) has a EV-to-FCF of -20.66 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TaiwanJ Pharmaceuticals Co and its competitors. According to the industry distribution chart, TaiwanJ Pharmaceuticals Co ranks #999999 out of 331 companies in the Biotechnology industry.
Is TaiwanJ Pharmaceuticals Co's EV-to-FCF too high?
TaiwanJ Pharmaceuticals Co's current EV-to-FCF is -20.66. Based on the distribution chart, TaiwanJ Pharmaceuticals Co ranks #999999 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TaiwanJ Pharmaceuticals Co has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TaiwanJ Pharmaceuticals Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiwanJ Pharmaceuticals Co ranks #999999 out of 331 companies for EV-to-FCF. This places TaiwanJ Pharmaceuticals Co in the lower half of its industry. The industry median EV-to-FCF is 16.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.48, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TaiwanJ Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiwanJ Pharmaceuticals Co's current EV-to-FCF is -20.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiwanJ Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, TaiwanJ Pharmaceuticals Co (ROCO:6549) is currently considered Possible Value Trap. The stock's GF Value™ is NT$11.94, compared to a current price of NT$7.13 — trading 40.3% below its estimated fair value. The current EV-to-FCF is -20.66. TaiwanJ Pharmaceuticals Co's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For TaiwanJ Pharmaceuticals Co (ROCO:6549), the current EV-to-FCF is -20.66 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiwanJ Pharmaceuticals Co (ROCO:6549) Overvalued in 2026?
Based on GuruFocus' analysis, TaiwanJ Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$7.13 is trading 40.3% below its estimated GF Value™ of NT$11.94.
GuruFocus considers TaiwanJ Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for ROCO:6549:
EV-to-FCF: -20.66
GF Value™: NT$11.94 vs. price of NT$7.13 (40.3% below fair value)
No single metric tells the full story. See the ROCO:6549 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiwanJ Pharmaceuticals Co Ltd is a Taiwan based specialty pharmaceutical company focused on small molecules for unmet medical needs like chronic organ inflammation of metabolic, autoimmune and infectious etiologies. It is also involved in developing novel chemical entities (NCEs) for chronic liver diseases and allergy/asthma.
46GF Score
Get the complete analysis for ROCO:6549
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6549 has been successfully added to your 
